PolyPeptide Group AG logo

PolyPeptide Group AG (PPGN)

Market Closed
10 Aug, 15:20
SIX SIX
43. 95
CHF
0
0%
CHF
1.26B Market Cap
- P/E Ratio
- Div Yield
32,154 Volume
-1.13 Eps
43.95 CHF
Previous Close
Add Transaction
Day Range
43.9 44
Year Range
21.8 50.1
Want to track PPGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

PPGN closed today higher at 43.95 CHF, an increase of 0% from yesterday's close, completing a monthly decrease of -5.6867% or -2.65 CHF. Over the past 12 months, PPGN stock gained 67.1103%.
PPGN is not paying dividends to its shareholders.
The last earnings report, released on Mar 12, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.2667%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on XMUN (EUR).

PPGN Chart

People also search for

Autoneum Holding AG
126.4 CHF
-1.25%

PolyPeptide Group AG (PPGN) FAQ

What is the stock price today?

The current price is 43.95 CHF.

On which exchange is it traded?

PolyPeptide Group AG is listed on SIX.

What is its stock symbol?

The ticker symbol is PPGN.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 1.26B.

Has PolyPeptide Group AG ever had a stock split?

No, there has never been a stock split.

PolyPeptide Group AG Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Juan Jose Gonzalez CEO
SIX Exchange
CH1110760852 ISIN
CH Country
1,440 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

PolyPeptide Group AG is a distinguished contract development and manufacturing organization (CDMO) with a global footprint spanning Europe, the United States, and India. Specializing in the development and production of synthetic peptides and oligonucleotides, the company plays a pivotal role in supplying active pharmaceutical ingredients (APIs) and intermediates for a wide array of therapeutic products. Founded in 1952 and based in Baar, Switzerland, PolyPeptide Group has established itself as a critical partner for pharmaceutical and biotechnology companies worldwide. With a track record of expertise and innovation in peptide-based therapies, it contributes significantly to advancements in healthcare. The company operates as a subsidiary of Draupnir Holding B.V., further solidifying its position within the pharmaceutical manufacturing landscape.

Products and Services

Peptide-Based Therapies for Metabolic Disorders: PolyPeptide Group specializes in the development of peptide-based therapies to address a variety of metabolic disorders. This includes GLP-1 receptor agonist drugs that are crucial in treating conditions such as type 2 diabetes, obesity, and associated co-morbidities. The company leverages state-of-the-art technology to offer innovative solutions that enhance patient care and outcomes in the field of metabolic health.

Oncology, Hormonal Disorders, Neurology, Ophthalmology, Cardiovascular, and Gastrointestinal Applications: The Group's extensive expertise spans a wide range of therapeutic areas beyond metabolic disorders. It provides tailor-made peptide solutions for treatments in oncology, hormonal imbalances, neurological conditions, eye diseases, heart-related ailments, and gastrointestinal issues. Through a combination of cutting-edge research and development capabilities, PolyPeptide supports the advancement of medical treatments across these vital healthcare sectors.

Cosmetic Peptides: Recognizing the growing demand for high-quality cosmetic ingredients, PolyPeptide has diversified its offerings to include peptides designed specifically for cosmetic applications. These high-purity peptides are used in various skincare and beauty products, offering anti-aging, moisturizing, and reparative benefits, among others. The company's foray into the cosmetics industry demonstrates its adaptability and commitment to meeting the evolving needs of its clients.

Individualized Peptide Therapeutics: In a groundbreaking approach to personalized medicine, PolyPeptide offers services related to individualized peptide therapeutics. This innovative service caters to the specific needs of patients and healthcare providers, enabling the development of customized peptide treatments tailored to the unique genetic and health profiles of individual patients. Through this personalized approach, PolyPeptide is at the forefront of delivering targeted and effective healthcare solutions.

Contact Information

Address: Neuhofstrasse 24, Baar, Switzerland, 6340
Phone: 41 435 020 580